Stocktoria

Organogenesis Holdings Inc. ORGO

Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2016-12-02
Chart by TradingView
3/9
Piotroski F — financial health
5.27
Altman Z″ — distress risk · safe
Dividend payout · no dividend

Financials & ratios (annual, from 10-K)

MetricFY2025FY2024FY2023FY2022FY2021
Financials
Revenue$564.2M$482.0M$433.1M$450.9M$467.4M
Gross profit$366.3M$326.7M$345.9M$353.2M
Operating income$44.7M-$1.3M$12.5M$22.3M$72.2M
Net income$37.0M$861,000$4.9M$15.5M$94.2M
Operating cash flow-$10.3M$14.2M$30.9M$24.9M$62.0M
Free cash flow-$24.5M$4.2M$6.6M-$9.0M$30.8M
Total assets$598.7M$497.9M$460.0M$449.4M$443.3M
Total liabilities$164.8M$112.6M$181.4M$183.7M$201.9M
Shareholders' equity$300.1M$262.9M$278.7M$265.7M$241.3M
Ratios
Gross margin76.0%75.4%76.7%75.6%
Operating margin7.9%-0.3%2.9%4.9%15.5%
Net margin6.6%0.2%1.1%3.4%20.2%
FCF margin-4.3%0.9%1.5%-2.0%6.6%
Return on assets6.2%0.2%1.1%3.5%21.3%
Return on equity12.3%0.3%1.8%5.8%39.0%
Debt / equity0.24×0.27×0.31×
Current ratio3.623.692.802.972.74
Revenue growth17.0%11.3%-3.9%-3.5%38.2%

Notable holders (13F)

InvestorSharesValue
RENAISSANCE TECHNOLOGIES LLC1,068,538$2.5M
Point72 Asset Management, L.P.148,358$351,608

Why these scores methodology →

Piotroski F-score: 3/9

  • Positive return on assets
  • Positive operating cash flow
  • Rising ROA
  • Cash flow exceeds net income
  • Lower long-term debt
  • Rising current ratio
  • No share dilution
  • Rising gross margin
  • Rising asset turnover

Altman Z″: 5.27 (safe)

  • Working capital / assets 0.438
  • Retained earnings / assets -0.005
  • EBIT / assets 0.075
  • Equity / liabilities 1.821

Sector peers

VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →

Source: SEC EDGAR filings · CIK 0001661181 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.